A 74-year-old retired teacher is brought to her primary care physician by her daughter due to progressive forgetfulness and difficulty managing her finances over the past two years. Her medical history includes well-controlled hypertension and hyperlipidemia. The physician suspects a major neurocognitive disorder. Arrange the following diagnostic steps in the most appropriate sequential clinical workflow, from the initial encounter to advanced diagnostic testing.
- 1Gather collateral history from the family and perform a comprehensive medication review.
- 2Administer a validated bedside cognitive screening instrument (e.g., Montreal Cognitive Assessment).
- 3Order routine laboratory evaluation to assess for reversible systemic or metabolic etiologies.
- 4Obtain structural brain imaging to evaluate for cerebrovascular disease, structural lesions, or specific atrophy patterns.
- 5Refer for formal specialized neuropsychological testing if the diagnosis remains ambiguous.
Answer
The correct sequential workflow is: 1) Clinical interview and medication review, 2) Objective bedside cognitive screening, 3) Laboratory testing for reversible causes, 4) Structural neuroimaging, and 5) Formal neuropsychological testing.
The evaluation of suspected major neurocognitive disorder follows a logical progression from least invasive and most fundamental to most specialized. It begins with a comprehensive history and medication review, as collateral information is vital and polypharmacy is a frequent culprit. This is immediately followed by a bedside cognitive screen (e.g., MoCA) to objectively quantify the deficit. Once impairment is confirmed, standard laboratory tests are drawn to rule out reversible metabolic or nutritional causes. Structural imaging follows to exclude macroscopic brain pathology such as tumors, bleeds, or hydrocephalus. Finally, if the diagnosis remains uncertain, formal neuropsychological testing is requested to clarify the specific neurocognitive domains affected.
Step-by-Step Solution
Key Concept
Standard diagnostic evaluation pathway for major neurocognitive disorders.